Envisagenics: Funding, Investors & Team (Sep 2026)
Envisagenics focus on the discovery of RNA therapeutics. Their mission is to reduce the complexity of biomedical data to accelerate the development of innovative therapeutic solutions through RNA splicing analytics and artificial intelligence. Over 30 million people in the US suffer from genetic diseases or cancer that could be caused by mutations affecting RNA splicing. 370 human diseases are known to be caused by splicing errors, and more remain to be discovered. Their breakthrough technology, SpliceCore, is a cloud-based platform that is experimentally validated to predict drug targets and biomarkers through splicing discovery from RNA-seq data, using Artificial Intelligence. We are using our software to identify splicing errors causative of diseases, identify the right drug targets, and develop RNA therapeutics through partnerships and collaborations with Biopharma. Their in-silico RNA therapeutics discovery platform replaces expensive drug-target selection and lead design with efficient computer simulations, decreasing time, cost, and failure risk of drug development programs. Envisagenics was founded in 2014 as a spinout of Cold Spring Harbor Laboratory.
Envisagenics has raised $27.0M across 2 funding rounds on record, the most recent a Series B of $25.0M announced in Jun 2024.
That round is above the $5.7M median round size for Artificial Intelligence companies tracked on FundedIQ over the last two years.
Envisagenics Company Profile and Key Stats
Latest funding round on record: Jun 2024.
Envisagenics Funding Rounds
Envisagenics raised $2.0M in a Grant announced in Aug 2022.
1.8 years later, a Series B of $25.0M was announced in Jun 2024.
Envisagenics Founders and Leadership Team
Contact details for the Envisagenics team: 1 of 1 has an email address on file.
Start 14-day free trial →Envisagenics Funding Compared to Other Artificial Intelligence Startups
Envisagenics' latest round of $25.0M is above the median round in Artificial Intelligence. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Envisagenics in Artificial Intelligence and New York
Companies Similar to Envisagenics
Cradlewise is an intelligent baby crib that learns from the baby's sleep patterns, spots the first signs of…
Capacity is an AI-powered helpdesk that automates support for customers and employees. Capacity connects…
AfterQuery is an artificial intelligence research and data platform focused on creating high-quality,…
The future of translation is conversational and Language I/O’s proprietary machine translation optimization…
Greptile is a platform driven by artificial intelligence that evaluates codebases and improves development…
Rhealth is a biotechnology company offering hospitals health management solutions utilizing advanced AI…
Socure is a predictive analytics platform for digital identity verification of consumers. Socure's predictive…
Instinct is an artificial intelligence startup developing AI technology.
Significant gives vehicle-mounted PC vision innovation that distinguishes visual deformities in network…
Cloverleaf AI exists to help you fill your pipeline with high-quality SLED leads. Tell us what you deliver,…
Emerald AI develops software and platforms that manage and coordinate energy use for artificial intelligence…
Envisagenics Funding FAQs
What does Envisagenics do?
Envisagenics focus on the discovery of RNA therapeutics. Their mission is to reduce the complexity of biomedical data to accelerate the development of innovative therapeutic solutions through RNA splicing analytics and artificial intelligence. Over 30 million people in the US suffer from genetic diseases or cancer that could be caused by mutations affecting RNA splicing. 370 human diseases are known to be caused by splicing errors, and more remain to be discovered. Their breakthrough technology, SpliceCore, is a cloud-based platform that is experimentally validated to predict drug targets and biomarkers through splicing discovery from RNA-seq data, using Artificial Intelligence. We are using our software to identify splicing errors causative of diseases, identify the right drug targets, and develop RNA therapeutics through partnerships and collaborations with Biopharma. Their in-silico RNA therapeutics discovery platform replaces expensive drug-target selection and lead design with efficient computer simulations, decreasing time, cost, and failure risk of drug development programs. Envisagenics was founded in 2014 as a spinout of Cold Spring Harbor Laboratory.
How much funding has Envisagenics raised?
Envisagenics has raised $27.0M across 2 rounds on record. The most recent is a Series B of $25.0M announced in Jun 2024.
When did Envisagenics last raise funding?
Envisagenics' most recent funding round on record is a Series B of $25.0M, announced in Jun 2024.
Who founded Envisagenics?
FundedIQ lists Maria Luisa Pineda (Founder) at Envisagenics.
Where is Envisagenics headquartered?
Envisagenics is based in New York, United States.
How many employees does Envisagenics have?
Envisagenics is in the 11-50 employee band.
How does Envisagenics' funding compare to other Artificial Intelligence startups?
Envisagenics' latest round of $25.0M is above the $5.7M median round size for Artificial Intelligence companies on FundedIQ across 7,234 tracked companies over the last two years.
About FundedIQ's Envisagenics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Envisagenics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.